Skip to content
Beacon

BIBProShares Ultra Nasdaq Biotechnology

Take a bet16y track recordRanked #320 of 775 in this goal

Seeks daily investment results that correspond to 2x the daily performance of the Nasdaq Biotechnology Index.

By ProShares · Launched 2010

Annual Cost

0.95%

#4,684 of 5,562 · expensive

Fund Size

$74M

#3,214 of 5,562 · mid-size

Return (1Y)Goal

+89.1%

Track Record

16 years

#768 of 5,562 · established

Performance

Total-return NAV · USD
Growth of $10,000
$21,820+118.2%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Strategy

Leveraged

Sector

Health care

Index tracked

Nasdaq Biotechnology Index

What it actually holds

By weight

Concentration

Top 10 holdings = 39.1% of fund✓ well diversified

N/A
5.8%
Amgen, Inc.
5.3%
Gilead Sciences, Inc.
4.9%
Vertex Pharmaceuticals, Inc.
4.9%
Regeneron Pharmaceuticals, Inc.
4.3%
N/A
3.3%
Alnylam Pharmaceuticals, Inc.
3.1%
N/A
2.6%
AstraZeneca plc
2.6%
N/A
2.5%

Asset allocation

Stocks
79.0%
Cash
17.9%
Other
3.1%

By sector

Healthcare
100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
40.3%High

Year-on-year price swings

Max drawdown
-66.2%Severe

Worst peak-to-trough loss

Sharpe (3Y)
0.48Below average
Sortino (3Y)
0.68Moderate downside risk

Where to buy

Listing

Exchange
NASDAQ Global Select Market

Full fund details

Objective
Seeks daily investment results that correspond to 2x the daily performance of the Nasdaq Biotechnology Index.
Strategy
Invests primarily in financial instruments to achieve 2x daily leveraged exposure to the Nasdaq Biotechnology Index. The Fund aims for daily returns consistent with its target, using a combination of derivatives.
Inception date
April 6, 2010
Fund family
ProShares

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Leveraged
Warning

Leveraged ETF — not a long-term hold

This fund uses leverage to amplify daily returns (e.g. 2x or 3x of an index). Daily rebalancing creates volatility decay — over weeks and months, the fund's return drifts from the stated multiple. In trending markets with low realised volatility, leveraged index ETFs can outperform their nominal multiple; in sideways or volatile markets they bleed. Designed for short-term tactical use, not buy-and-hold.

Source: Cheng & Madhavan, 'The Dynamics of Leveraged and Inverse ETFs' (2009)

Why we flagged this: strategy=leveraged + leveraged_name_or_strategy

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've reviewed BIB. Save it to your watchlist to track it alongside the other funds you're weighing.

Data updated on 2026-06-19